Levomilnacipran

From Wikipedia, the free encyclopedia - View original article

Levomilnacipran
Systematic (IUPAC) name
(1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide
Clinical data
Legal statusRx-Only
RoutesOral
Identifiers
CAS number96847-55-1 YesY
175131-60-9 (hydrochloride)
ATC codeNone
PubChemCID 6917779
ChemSpider5293005 N
UNIIUGM0326TXX YesY
KEGGD10072 N
Chemical data
FormulaC15H22N2O 
Mol. mass246.348 g/mol
 N (what is this?)  (verify)
 
Jump to: navigation, search
Levomilnacipran
Systematic (IUPAC) name
(1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide
Clinical data
Legal statusRx-Only
RoutesOral
Identifiers
CAS number96847-55-1 YesY
175131-60-9 (hydrochloride)
ATC codeNone
PubChemCID 6917779
ChemSpider5293005 N
UNIIUGM0326TXX YesY
KEGGD10072 N
Chemical data
FormulaC15H22N2O 
Mol. mass246.348 g/mol
 N (what is this?)  (verify)

Levomilnacipran (F2695) is an antidepressant developed by Forest Laboratories and Pierre Fabre Group for the treatment of depression.[1][2][3] As of 2009 it was in phase III clinical trials.[4] Levomilnacipran is an active enantiomer of milnacipran and therefore has similar effects and pharmacology, acting as a serotonin-norepinephrine reuptake inhibitor.[2][5] On 20 January 2011, Forest and Pierre Fabre Medicament announced that levomilnacipran was no better than placebo in a late-stage clinical trial. Two other late-stage trials will be finished in mid-2011. The FDA approved the product, which is to be sold as Fetzima, in July 2013.[6]

See also[edit]

References[edit]